\
&
Contact us
\
&
Contact us
This was 5 years ago
Location ProgrammesAn information session on the Marie Skłodowska-Curie Actions (MSCA) 2020 call for proposals for the Research and Innovation Staff Exchange (RISE) was organised by the Belgian Science Policy Office (BELSPO), the Fund for Scientific Research – FNRS (F.R.S.-FNRS) and NCP Flanders.
The information session was organised to support researchers/research organisations/industry in the preparation of their MSCA RISE application.
RISE funds short-term exchanges for staff to develop careers combining scientific excellence with exposure to other countries and sectors. RISE enables more interaction between academia and non-academic organisations within Europe and worldwide.
Participation to the session was free and open to any researcher wishing to apply with a Belgian Host Institution, or any staff member of a Belgian Host Institution. Registration was mandatory.
The presentations are available on the event website and below.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
